Pyra­mid inks TROP2 pact with Chi­na biotech to fol­low suit of Gilead, As­traZeneca-Dai­ichi Sankyo

Look­ing to go where Gilead al­ready is and where As­traZeneca-part­nered Dai­ichi Sankyo is head­ed, Pyra­mid Bio­sciences has locked in a pact for a TROP2-tar­get­ed an­ti­body …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER